Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 8, Issue 5, Pages 707-716Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.8.5.707
Keywords
brain tumor; glioblastoma; topoisomerase inhibitor
Categories
Ask authors/readers for more resources
Patients with primary malignant brain tumors have a poor prognosis. Standard treatment includes surgical resection, radiation therapy and chemotherapy. Topoisomerase I inhibitors such as topotecan and irinotecan (CPT-11) represent one class of chemotherapy drugs that have been used in this disease. Recent clinical trials have shown major antitumor activity in recurrent glioblastoma when adding the antiangiogenesis drug bevacizumab with CPT-11. The combination of targeted agents to topoisomerase I inhibitors represent a novel and promising approach. This review will summarize clinical trials with topoisomerase I inhibitors and discuss new treatment strategies for primary malignant brain tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available